Anti-aging cosmetic compositions prepared from conditioned medium of adipose-derived stem cells are provided. The cosmetic compositions are preferably ready-to-mix compositions, comprising two separate components: a protein component in a dried form that serves as the cosmetically active ingredient of the product, comprising a protein fraction purified from an adipose-derived stem cell conditioned medium; and a reconstitution component, for reconstituting the lyophilized protein component just before application to the skin.

Anti-aging cosmetic compositions prepared from conditioned medium of adipose-derived stem cells are provided. The cosmetic compositions are preferably ready-to-mix compositions, comprising two separate components: a protein component in a dried form that serves as the cosmetically active ingredient of the product, comprising a protein fraction purified from an adipose-derived stem cell conditioned medium; and a reconstitution component, for reconstituting the lyophilized protein component just before application to the skin.

Provided herein are compositions comprising a DR6 peptide; and methods for treating cancer and/or a tumor, including a platinum drug resistant tumor or cancer, in a patient in need thereof.

Provided herein are compositions comprising a DR6 peptide; and methods for treating cancer and/or a tumor, including a platinum drug resistant tumor or cancer, in a patient in need thereof.

The disclosure provides immunogenic peptides, compositions, means, and methods for treating Alzheimer's disease or mild cognitive impairment. The disclosure further provides means and methods for diagnosing patients, selecting patients for treatment, and/or evaluating the efficacy of treatment for Alzheimer's disease or mild cognitive impairment.

Disclosed herein are formulations with improved stability or reduced viscosity that comprise a therapeutic protein and a lyo-enhancing excipient, wherein the improved stability formulation is characterized by improved stability in comparison to a control formulation otherwise identical to the stability-enhanced formulation but lacking the lyo-enhancing excipient, and the reduced viscosity formulation is characterized by reduced viscosity in comparison to a control formulation otherwise identical to the reduced viscosity formulation but lacking the lyo-enhancing excipient. Further disclosed herein are methods of improving stability of therapeutic formulations, reducing viscosity of therapeutic formulations, or improving parameters of lyophilization processes.

Cationic polymers having one or more anionic ligand end groups, including a new class of carboxylated branched poly(beta-amino ester)s that can self-assemble into nanoparticles for efficient intracellular delivery of different biomolecules, including a variety of proteins is disclosed.

The present invention discloses an aqueous pharmaceutical composition containing a protein in which serum albumin and growth hormone are linked. The aqueous pharmaceutical composition contains, as an active ingredient, a fusion protein of human serum albumin and human growth hormone; the concentration of the fusion protein is 10-100 mg/mL; the concentration of sucrose is 10-150 mg/mL; the concentration of a nonionic surfactant is 0.15-10 mg/mL; the concentration of a preservative is 0.5-12 mg/mL; the concentration of a buffer is 1-30 mM; and the pH is 5.0-8.0.

This document relates to non-covalently bound complexes comprising cabazitaxel and human serum albumin. This document also relates to compositions comprising non-covalently bound complexes comprising cabazitaxel and human serum albumin. This document also relates to compositions comprising cabazitaxel and human serum albumin. This document also relates to compositions consisting essentially of cabazitaxel and human serum albumin.

This document relates to non-covalently bound complexes comprising cabazitaxel and human serum albumin. This document also relates to compositions comprising non-covalently bound complexes comprising cabazitaxel and human serum albumin. This document also relates to compositions comprising cabazitaxel and human serum albumin. This document also relates to compositions consisting essentially of cabazitaxel and human serum albumin.